Fattiviracin A1, showed potent antiviral activities against herpes simplex virus type 1 (HSV-1), varicella-zoster virus (VZV), influenza A virus and human immunodeficiency virus type 1(HIV-1). It showed no cytotoxicity against Vero cells. Fattiviracin A1 exhibited no significant antibacterial or antifungal activities. Treatment of HSV-1 with fattiviracin A1 decreased its infectivity to Vero cells. The mechanism of its antiviral activity may be due to inactivation of the viral particles and inhibition of viral entry into host cells.
Fattiviracin A1 (Fig. 1 ) is a novel antiviral agent isolated from the culture filtrate of Streptomyces microflavus strain No. 2445. Its taxonomy, production, isolation, physico-chemical properties and structure elucidation have been already reported in the preceding paper1). In this paper we describe its biological properties. Materials and Methods
Antiviral and Cell Growth Assays
The antiviral activities of fattiviracin A1 on HSV-1 (KOS), VZV and influenza A virus (H1N1) were measured by the plaque reduction assay2). Confluent monolayers of Vero cells in 6-well plates were infected with 100 PFU of HSV-1 or VZV. Confluent monolayers of MDCK cells were infected with 100 PFU of influenza A virus. After a 1 hour adsorption period, the cultures were overlaid with DULBECCO'S modified Eagle minimum essential medium (DMEM) containing 2% heat-inactivated fetal calf serum (FCS) including various concentrations of the drug. The plates were incubated in the CO2 incubator for 3 days, then fixed with formalin and stained with crystal violet in methanol. Infectious virus production was quantified by observing the virus-induced cytopathic effect. were added, and incubation was continued for 3 days.
The dose response curve of fattiviracin A1 is shown in Fig. 2 Compound 4 (Fig. 3) , one of the degradation products of fattiviracin A1, was examined for antiviral activity. It HSV-1. This result suggests that the long fatty acid chain of fattiviracin A1 may play an important role in its antiviral activity. Fig. 3 . Deduced structure of compound 4.
A1 on Infected Cells
As shown in Fig. 4A From these results, it is suggested that the antiviral mechanism of fattiviracin A1 is due to inactivation of viral particles and inhibition of viral entry into the host cells. The detailed anti-HIV mechanisms of fattiviracin A1 will be reported in the future.
